DEALS and DATA
A late but prolific bloomer: After 20 years and $200 million, Isis is flirting with profitability.
Cadence Pharmaceuticals is preparing to launch its intravenous pain medication.
Sorrento Therapeutics announced a reverse merger with QuikByte Software.
There IS some investment money out there. Just ask Nexus Biosystems and Helixis.
InnerCool Therapies, a subsidiary of Cardium Therapeutics, gets technology validation and a new owner.
The Voice of San Diego's David Washburn takes a look at the action on Capitol Hill regarding biosimilars, and highlights all the work BIOCOM has been doing on the issue in Washington DC.
Genoptix signed a six-year lease at the Carlsbad Research Center. The deal is valued in excess of $3 million. Lannie Allee and Roger Carlson of CB Richard Ellis represented the landlord, Reynolds Family Trust. The Blackmore Co. represented Genoptix.
On July 13, Victory Pharma announced the NDA for its first drug had been accepted for review by the FDA. But the privately-held San Diego company had some unforeseen bad news, too. Sciele Pharma, of Atlanta, a unit ofJapan’s Shionogi & Co., called off its acquisition of Victory for $150 million. Sciele, which had announced the acquisition in May, said the deal break-up was due to “unforeseen” developments. Xconomy reports that it found an FDA advisory committee call for banning drugs that combine acetaminophen and narcotics, which could impact two Victory Pharma products.
Amgen appoints Harvard professor to its board.
LPath replaces its outside auditor.
Somaxon renews its insomnia drug application.
An angel’s view on San Diego’s venture capital landscape.
Arena raises funds.
What’s a company to do if it doesn’t get enough shareholder votes to approve its dissolution plan?
The National Institutes of Health released its final draft of the guidelines for stem cell research that will be eligible for federal funding.Research on parthenogenic stem cells, which involve embryonic stemcells taken from unfertilized eggs that could never become a viableembryo, is not permitted under the guidelines. BIOCOM had opposed thisrestriction in a letter to the NIH. International Stem Cells Inc., aBIOCOM member company in Oceanside, has developed embryonic stem celllines using parthenogenic cells.